METTL14 and colorectal cancer: Similarly, in pMMR-MSI-L colorectal cancer, METTL14 promotes YTHDF2-dependent degradation of Stat1/Irf1 mRNA, dampening IFN-γ–Stat1–Irf1 signaling and limiting CD8+ T-cell activity, which restricts PD-1 immunotherapy response (Figure 2).